Literature DB >> 18054641

Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis.

Sophie M Jones1, Joel M Weinstein, Phillippa Cumberland, N Klein, Ken K Nischal.   

Abstract

OBJECTIVE: To describe the cause, management, and effect of chronic blepharokeratoconjunctivitis (BKC) on the cornea and visual function in children.
DESIGN: Noncomparative, interventional, retrospective case series. PARTICIPANTS: Twenty-seven children with BKC.
METHODS: Presenting age, best-corrected visual acuity (BCVA), refractive error, and any corneal or eyelid pathologic features were recorded. Treatment included modified lid hygiene, topical antibiotics, and steroids. Systemic therapy included oral antibiotics and, from 2003 onward, flaxseed oil as an alternative to long-term antibiotics. Amblyopia therapy included refractive correction, occlusion, or atropine therapy. MAIN OUTCOME MEASURES: Corneal and eyelid status, visual acuity (VA), and refractive error at final examination.
RESULTS: Mean age at presentation was 6.9 years (range, 7 months-15.9 years), and mean follow-up was 2.3 years (range, 5 months-6.1 years). All patients had discomfort, conjunctival injection, and signs of posterior blepharitis at presentation. Photophobia was reported in 14 patients (52%), whereas anterior eyelid inflammation was noted in 6 (22%). Acne rosacea was confirmed in 3 patients (11%). Corneal involvement occurred in 44 eyes (81%), and a history of recurrent chalazia was seen in 18 patients (67%). Median monocular BCVAs in affected eyes were 0.28 logarithm of the minimum angle of resolution (logMAR) units (interquartile range [IqR], 0.02-0.40) at presentation and 0.02 logMAR units (IqR, 0.00-0.18) at last visit. Best-corrected VA improved in 70% of affected eyes and remained unchanged in 30%. Superimposed amblyopia was present and treated in 15 patients (48%). All 8 patients (20%) who failed to achieve VA of 0.2 logMAR units or better at the final examination had bilateral corneal involvement at presentation. One child experienced a systemic side effect from oral antibiotics. No child had significant side effects from topical treatment. Twelve patients (44%) received flaxseed oil as part of their tapering regimen. A 2-year lag between symptom onset and treatment resulted, on average, in a reduction of 0.06 logMAR units of VA (95% confidence interval, 0.00-0.12; P = 0.054).
CONCLUSIONS: These findings suggest that visual loss may be significant in BKC and that delayed treatment may result in decreased final BCVA. Adequate management needs both topical and systemic treatment. Flaxseed oil may be an effective antiinflammatory nutritional therapy alternative to long-term antibiotics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18054641     DOI: 10.1016/j.ophtha.2007.01.021

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

1.  Amblyopia and strabismus by monocular corneal opacity following suspected epidemic keratoconjunctivitis in infancy.

Authors:  Byoungyoung Gu; Junhyuk Son; Myungmi Kim
Journal:  Korean J Ophthalmol       Date:  2011-07-22

2.  Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.

Authors:  Timothy L Comstock; Michael R Paterno; Kirk M Bateman; Heleen H Decory; Matthew Gearinger
Journal:  Paediatr Drugs       Date:  2012-04-01       Impact factor: 3.022

Review 3.  Topical treatments for blepharokeratoconjunctivitis in children.

Authors:  Michael O'Gallagher; Catey Bunce; Melanie Hingorani; Frank Larkin; Stephen Tuft; Annegret Dahlmann-Noor
Journal:  Cochrane Database Syst Rev       Date:  2017-02-07

Review 4.  [Dry eye syndrome and neurotrophic keratitis in childhood. Causes and therapy].

Authors:  T Dietrich; A B Renner; H Helbig; I M Oberacher-Velten
Journal:  Ophthalmologe       Date:  2010-10       Impact factor: 1.059

5.  Blepharokeratoconjunctivitis in childhood: corneal involvement and visual outcome.

Authors:  A Rodríguez-García; S González-Godínez; S López-Rubio
Journal:  Eye (Lond)       Date:  2015-12-04       Impact factor: 3.775

6.  Oral azithromycin combined with topical anti-inflammatory agents in the treatment of blepharokeratoconjunctivitis in children.

Authors:  Daniel S Choi; Ali Djalilian
Journal:  J AAPOS       Date:  2013-01-27       Impact factor: 1.220

Review 7.  Systemic treatment for blepharokeratoconjunctivitis in children.

Authors:  Michael O'Gallagher; Marina Banteka; Catey Bunce; Frank Larkin; Stephen Tuft; Annegret Dahlmann-Noor
Journal:  Cochrane Database Syst Rev       Date:  2016-05-30

8.  Evaluation of the ocular surface characteristics and Demodex infestation in paediatric and adult blepharokeratoconjunctivitis.

Authors:  Mengliang Wu; Xiaochun Wang; Jing Han; Tingting Shao; Yan Wang
Journal:  BMC Ophthalmol       Date:  2019-03-07       Impact factor: 2.209

Review 9.  Diagnosis, Management, and Treatment of Vernal Keratoconjunctivitis in Asia: Recommendations From the Management of Vernal Keratoconjunctivitis in Asia Expert Working Group.

Authors:  Jodhbir S Mehta; Wei-Li Chen; Arthur C K Cheng; Le Xuan Cung; Ivo J Dualan; Ramesh Kekunnaya; Nurliza Khaliddin; Tae-Im Kim; Douglas K Lam; Seo Wei Leo; Florence Manurung; Nattaporn Tesavibul; Dominique Bremond-Gignac
Journal:  Front Med (Lausanne)       Date:  2022-08-01

10.  Simultaneous Subconjunctival Triamcinolone and Bevacizumab Injections for Management of Blepharokeratoconjunctivitis in Children.

Authors:  Chu Luan Nguyen; Tony S Chen; Khoi Tran; James E H Smith; Noni Lewis
Journal:  Case Rep Ophthalmol Med       Date:  2018-06-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.